22/10/2026 AstraZeneca commercializes ZEGFROVY® following US FDA approval in EGFR exon 20 insertion NSCLC AstraZeneca commercializes ZEGFROVY® following US FDA approval in EGFR exon 20 insertion NSCLC (Ref) AstraZeneca announced the US availability of ZEGFROVY® (sunvozertinib; EGFR-TKI), a targeted therapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed following